Duration of Adalimumab Therapy for Hidradenitis Suppurativa
Patients with hidradenitis suppurativa should be maintained on adalimumab 40 mg weekly indefinitely as long as they demonstrate at least a partial response, as discontinuation leads to disease relapse in the majority of patients.
Treatment Duration Framework
Initial Assessment Period (12 Weeks)
- Evaluate response at week 12 using HiSCR (≥50% reduction in abscess and inflammatory nodule count with no increase in abscesses or draining fistulas) 1
- Patients who achieve at least partial response by week 12 should continue weekly dosing, as approximately 40% of initial non-responders achieve response by week 36 with continued treatment 1
- Discontinue therapy in patients showing no response by week 12, as they are unlikely to benefit from continued treatment 2
Maintenance Therapy (Beyond 12 Weeks)
- Continue adalimumab 40 mg weekly indefinitely for responders and partial responders 3, 2
- Do not reduce to every-other-week dosing after achieving response, as this leads to inferior outcomes compared to continued weekly dosing (week 36 HiSCR: 48.1% with weekly vs 46.2% with every-other-week vs 32.1% with placebo) 2
- Sustained efficacy is maintained through at least 168 weeks (over 3 years) with continuous weekly dosing, with 52-57% of patients maintaining HiSCR response 3
Long-Term Considerations
Real-world data demonstrates:
- 69% of patients achieve HiSCR at week 24, increasing to 82% at week 52 in patients with medium baseline abscess/nodule counts and 75% in those with high counts 4
- Continuous weekly dosing maintains response with sustained improvements in lesion counts, pain scores, and quality of life measures through extended follow-up 3
- No new safety signals emerge with long-term use beyond those observed in initial trials 3
Critical Pitfalls to Avoid
Premature dose reduction: Switching from weekly to every-other-week dosing after initial response results in loss of disease control in a substantial proportion of patients 2. The data clearly show weekly dosing is superior for maintenance.
Early discontinuation: Almost half of week-12 responders lose response at week 36 if switched to placebo, compared to maintaining response with continued weekly dosing 1. Conversely, three-quarters of patients switched to placebo lose their response 1.
Inadequate trial duration: Some patients require up to 36 weeks to achieve response, so discontinuing therapy before this timeframe in partial responders may be premature 1
Dose Intensification Option
For patients with inadequate response to standard weekly dosing, consider increasing to 80 mg weekly, though evidence is limited 5. Both 40 mg weekly and 80 mg every 2 weeks show similar efficacy in comparative studies, with no statistical differences in clinical outcomes or quality of life improvements 6.
Safety Monitoring During Long-Term Therapy
- Screen for tuberculosis prior to initiation using TST and/or IGRA 1
- Initiate TB prophylaxis at least 1 month before adalimumab in patients with latent TB not at high risk 1
- Monitor for hepatitis B reactivation in at-risk patients, with prophylactic antiviral therapy (entecavir or tenofovir) preventing reactivation 7
- Annual TB screening if using concomitant glucocorticoids exceeding 15 mg prednisone equivalent daily for ≥4 weeks 1